The most common strategy in siRNA formulations is targeting proteins that act as key effectors in signaling pathways that regulate tumor growth, survival, and invasion (e.g., PLK1, PKN3, EphA2, KRAS, TGF-β1, COX-2, BCL2L12, VEGF, GSTP) [553]. This evidence concerns the gene PLK1 and neoplasm.